Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RIGL with free AI briefings, catalyst countdowns, and dilution alerts.

RIGL · Rigel Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$120.7M Cash on Hand
CF+ Cash Runway
13.9% Short Interest
$64.4 Analyst Target (5)
Follow RIGL by email Get an email when RIGL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RIGL, unsubscribe in one click. Privacy

📣 What RIGL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Olutasidenib
FDA approved Dec 2022 · Rezlidhia
AML (Acute Myeloid Leukemia) Phase 4 · NCT07486713 Recruiting
Pralsetinib
FDA approved Sep 2020 · Gavreto
NSCLC (Non-small Cell Lung Cancer) Phase 4 · NCT07704658 Recruiting
Fostamatinib
FDA approved Apr 2018 · Tavalisse
Covid19 Phase 3 · NCT04629703 Completed
Vepdegestrant
FDA approved May 2026 · Veppanu
Breast Cancer Phase 1/2 · NCT06125522 Terminated
Imiquimod Actinic Keratoses Phase 4 · NCT00774787 Completed
Cytochrome P450 1A2 AML (Acute Myeloid Leukemia) Phase 4 · NCT07486713 Recruiting
Cytochrome P450 3A4 NSCLC (Non-small Cell Lung Cancer) Phase 4 · NCT07704658 Recruiting
R926112 Rhinitis, Allergic, Seasonal Phase 2 · NCT00115089 Completed
Gilteritinib Targeted Therapy Phase 2 · NCT07032727 Recruiting
LY3871801 Rheumatoid Arthritis Phase 2 · NCT05848258 Completed
Temozolomide High Grade Glioma Phase 2 · NCT06161974 Recruiting
R348 Ophthalmic Solution, 0.2% Chronic Graft-versus-host Disease Phase 2 · NCT02040623 Completed
R348 Ophthalmic Solution, 0.5% Chronic Graft-versus-host Disease Phase 2 · NCT02040623 Completed
R788 Rheumatoid Arthritis Phase 2 · NCT00326339 Completed
Dual IRAK1/4 Inhibitor R906289 Monosodium Low Risk Myelodysplastic Syndromes Phase 1/2 · NCT05308264 Recruiting
R932333 Lupus Erythematosus, Discoid Phase 2 · NCT01597050 Completed

Also used in these trials (approved or third-party drugs, not RIGL's own candidates): Ruxolitinib, Venetoclax, Azacitidine, Cladribine, Cytarabine, Decitabine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RIGL holds $120.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RIGL files for a raise →

👥 Who Owns RIGL

Insiders 3.3% Institutions (247 holders) 96.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 2,065,776 10.97% 2026-09-30
Soleus Capital Master Fund, L.P. Institution (13G, 5%+) 1,843,504 9.79% 2026-06-30
Soleus Capital Management, L.P. Institution (13F) 1,843,504 9.79% 2026-09-30
Armistice Capital, LLC Institution (13G, 5%+) 1,672,000 8.88% 2026-06-30
Morgan Stanley Institution (13G, 5%+) 1,212,656 6.44% 2026-09-30
American Century Companies Inc Institution (13F) 1,043,966 5.54% 2026-09-30
State Street Corporation Institution (13F) 879,862 4.67% 2026-09-30
LSV Asset Management Institution (13F) 787,408 4.18% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 782,703 4.16% 2026-09-30
Assenagon Asset Management S.A. Institution (13F) 535,685 2.84% 2026-09-30
Geode Capital Management, LLC Institution (13F) 482,976 2.56% 2026-09-30
Raul R Rodriguez
CEO, President, Director · +31,700 options
Insider 273,362 1.45% 2026-09-01

Share count 18,829,972 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-02
filed 2026-09-03
Schorno Dean L
Option exercise (M) 2,000 – –
2026-09-02
filed 2026-09-03
Schorno Dean L
Option exercise (M) 620 – –
2026-09-02
filed 2026-09-03
Schorno Dean L
Option exercise (M) 694 – –
2026-09-02
filed 2026-09-03
Schorno Dean L
Option exercise (M) 1,286 $24.20 82,962
2026-09-02
filed 2026-09-03
Schorno Dean L
Option exercise (M) 2,000 $24.20 81,676

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full RIGL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RIGL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.